Uterine smooth muscle tumors of uncertain malignant potential (STUMP): A case report.

INTRODUCTION: Uterine smooth muscle tumors of uncertain malignant potential (STUMP) are extremely rare, defined as a uterine smooth muscle tumors that cannot be diagnosed as benign or malignant and does not satisfy all the criteria for leiomyosarcoma or leiomyoma. CASE REPRESENTATION: A 48-year-old woman who presented with a history of heavy menstrual bleeding and pelvic pain. Physical examination revealed an enlarged uterus. Ultrasonography showed lobular and enlarged uterus containing multiples leiomyomas. A subtotal hysterectomy was performed. A Pathological analysis revealed a uterine mass diagnosed as a smooth muscle tumor of uncertain malignant. DISCUSSION: Uterine STUMPs are rare and are commonly diagnosed by histopathological evaluation following myomectomy or hysterectomy. The most common clinical manifestations of uterine STUMP are the same as leiomyomas. Prognosis for the patient is unclear and there is a risk of recurrence with the tumors. However, considering their potential risk of recurrence and metastasis, it is advisable to maintain six-monthly controls for 5 years and then annual controls for 5 years more. CONCLUSION: Due to the rarity of uterine STUMP, there are no specific guidelines for their treatment and control. The scientific literature needs to be constantly updated in order to identify masses suspected of malignancy before surgery and improve patient management and follow-up.

Predictors of herbal medicine use among cancer patients.

PURPOSE: Moroccan studies have shown a high frequency of use of traditional and complementary medicines (T&CM). No survey has investigated the predictive factors of the use of traditional herbal medicine. This study aims to assess the prevalence, the determinants, and the predictors of this use. METHODS: At the regional oncology center of Beni Mellal, we conducted a descriptive and analytical cross-sectional study with 530 adult cancer patients chosen by quota sampling. A 54-item questionnaire was used to perform the face-to-face survey. The Complementary and Alternative Medicine (CAM) healthcare model was used to create this instrument. RESULTS: The prevalence of traditional herbal medicine use was 36.6%. Several variables of the conceptual model were associated with the use of herbal medicine (gender, attitude, and belief towards T&CM, financial resources, and clinical characteristics of patients) (p < 0.05). Predictors of traditional herbal medicine use were female gender (OR = 4.687; p < 0.000), social impact of cancer (OR = 2.314; p < 0.05), emotional impact of cancer (OR = 2.314; p < 0. 05), expected benefits of T&CM use (OR = 3.453; p < 0.000), perceived scientific barriers (OR = 0.580; p < 0.000), perceived socioeconomic barriers (OR = 0.657; p < 0.005), and social norms of relatives (OR = 3.238; p < 0.000). CONCLUSION: The use of herbal medicine is quite frequent. The profile of users is represented by women who experience pain and the psychosocial impact of cancer and who have positive beliefs about TCMs, are influenced by their relatives and who did not perceive the barriers of this use.

Metastatic giant basal cell carcinoma: a case report.

Basal cell carcinoma is the most common skin cancer, characterised by a slow growing behavior, metastasis are extremely rare, and it occurs in less than 0, 1% of all cases. Giant basal cell carcinoma is a rare form of basal cell carcinoma, more aggressive and defined as a tumor measuring more than 5 cm at its largest diameter. Only 1% of all basal cell carcinoma develops to a giant basal cell carcinoma, resulting of patient's negligence. Giant basal cell carcinoma is associated with higher potential of metastasis and even death, compared to ordinary basal cell carcinoma. We report a case of giant basal cell carcinoma metastaticin lung occurring in a 79 years old male patient, with a fatal evolution after one course of systemic chemotherapy. Giant basal cell carcinoma is a very rare entity, early detection of these tumors could prevent metastasis occurrence and improve the prognosis of this malignancy.

Atypical reversible leucoencephalopathy syndrome after bevacizumab/folfox regimen for metastatic colon cancer.

We are reporting a case of multifocal reversible leucoencephalopathy syndrome induced by chemotherapy based on Folfox-Bevacizumab regimen. A 44-year-old female, with no history of hypertension, received a chemotherapy based on Folfox-Bevacizumab for her metastatic colon cancer (5 FU: 325 mg/m(2) d1 by intravenous infusion, Oxaliplatin 80 mg/m(2) d1, and Bevacizumab: 7.5 mg/Kg d1). During the fourth cure, she presented delirium, seizures, and visual disturbances. The computed tomography (CT) of the brain showed hypodense lesions of the white matter of frontal, parietal, and occipital lobes, which were bilateral and symmetrical. The clinical table was reversible under symptomatic treatment.